To honour the legacy and memory of Myeloma Canada’s co-founder, the Aldo Del Col Research Grant funds patient-prioritized Canadian research projects that help address the knowledge gaps in the diagnosis and treatment of myeloma and/or related plasma cell disorders that were identified through the Myeloma Priority Setting Partnership (PSP).
The Myeloma PSP is a collaborative project between the Horizon Health Network, the Maritime SPOR SUPPORT UNIT (MSSU), and Myeloma Canada, and adhered to established PSP practices set by the James Lind Alliance. Click here to read the published correspondence, “The future of myeloma research in Canada and beyond: results of a James Lind Alliance priority setting partnership”.
Based on the number and quality of applications, Myeloma Canada intends to contribute CDN $300,000 to this grant competition, with an additional CDN $300,000 potentially available through equal co-funding partnerships with:
- Cell Therapy Transplant Canada
- Cancer Research Society
- The Leukemia & Lymphoma Society of Canada
- Myeloma Foundation 8849m
The minimum grant award is CDN $75,000 and the maximum grant award is CDN $150,000.
Applications will be accepted from April 9 – June 6, 2025. Funding decisions will be communicated to applicants in October 2025, or earlier. The principal applicant must be a researcher at any career stage, and be affiliated with a Canadian university, hospital, cancer centre, or research institute.
Indirect costs of research (e.g., institutional overhead, pooled costs, G&A, M&A, utilities, maintenance) are not permitted.
2025 Aldo Del Col Research Grant
To honour the legacy and memory of Myeloma Canada’s co-founder, the Aldo Del Col Research Grant funds patient-prioritized Canadian research projects that help address the knowledge gaps in the diagnosis and treatment of myeloma and/or related plasma cell disorders that were identified through the Myeloma Priority Setting Partnership (PSP).
The Myeloma PSP is a collaborative project between the Horizon Health Network, the Maritime SPOR SUPPORT UNIT (MSSU), and Myeloma Canada, and adhered to established PSP practices set by the James Lind Alliance. Click here to read the published correspondence, “The future of myeloma research in Canada and beyond: results of a James Lind Alliance priority setting partnership”.
Based on the number and quality of applications, Myeloma Canada intends to contribute CDN $300,000 to this grant competition, with an additional CDN $300,000 potentially available through equal co-funding partnerships with:
- Cell Therapy Transplant Canada
- Cancer Research Society
- The Leukemia & Lymphoma Society of Canada
- Myeloma Foundation 8849m
The minimum grant award is CDN $75,000 and the maximum grant award is CDN $150,000.
Applications will be accepted from April 9 – June 6, 2025. Funding decisions will be communicated to applicants in October 2025, or earlier. The principal applicant must be a researcher at any career stage, and be affiliated with a Canadian university, hospital, cancer centre, or research institute.
Indirect costs of research (e.g., institutional overhead, pooled costs, G&A, M&A, utilities, maintenance) are not permitted.